BioSpace News Archive

Karmanos Cancer Institute is pleased to announce that it will begin using the OncoLens cancer treatment planning software platform to hold tumor boards and multidisciplinary case discussions.

Also Includes a New Donation of Personal Protective Equipment (PPE) Directed Toward Health Workers in Underserved Communities Worldwide

Exactech, a developer and producer of innovative implants, instrumentation and the Active Intelligence® platform of technologies for joint replacement surgery, announced today the launch of Predict+™, a data-driven, clinical decision support tool that uses machine learning to predict individual patient outcomes after shoulder replacement surgery to assist surgeon decision making.

The 2020 American Geophysical Union Fall Meeting will include a feature presentation from Battelle Chief Scientist Mike Kuhlman, National Ecological Observatory Network Chief Scientist and Observatory Director Paula Mabee, Battelle Senior Project Manager Tom Hutchings, and Systems Integration Specialist Nicolas Romano.

Publication in Nature Communications demonstrates robust neutralizing antibodies and T cell responses against SARS-CoV-2

Company flexes infrastructure, collaborates even more transparently with provider partners to drive impact during pandemic

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference

IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced that William Ho, Chief Executive Officer of IN8bio, will present at the 3rd Annual Evercore ISI HealthCONx Conference

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $60,000,000 of shares of its common stock.

Arrowhead Pharmaceuticals, Inc. announced that it is scheduled to participate in the following upcoming events